⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AXSM News
Axsome Therapeutics, Inc
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
globenewswire.com
AXSM
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
globenewswire.com
AXSM
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
globenewswire.com
AXSM
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
globenewswire.com
AXSM
Donald Webbe Awarded Richard Adams Leadership Award by Fiver Children’s Foundation
globenewswire.com
AXSM
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
globenewswire.com
AXSM
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
globenewswire.com
AXSM
CaringKind 30th Anniversary Forget-Me-Not Gala
prnewswire.com
BMY
AXSM
ACAD
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
AXSM
IGC
Form 8-K
sec.gov
AXSM